| 4.71 0.12 (2.61%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.77 | 1-year : | 6.74 |
| Resists | First : | 4.94 | Second : | 5.77 |
| Pivot price | 4.54 |
|||
| Supports | First : | 4.42 | Second : | 4.09 |
| MAs | MA(5) : | 4.57 |
MA(20) : | 4.53 |
| MA(100) : | 3.88 |
MA(250) : | 3.56 |
|
| MACD | MACD : | 0 |
Signal : | 0  |
| %K %D | K(14,3) : | 48.8 |
D(3) : | 40.3 |
| RSI | RSI(14): 57.9 |
|||
| 52-week | High : | 5.09 | Low : | 2.71 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ABUS ] has closed below upper band by 21.5%. Bollinger Bands are 2.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.72 - 4.73 | 4.73 - 4.75 |
| Low: | 4.41 - 4.43 | 4.43 - 4.46 |
| Close: | 4.67 - 4.71 | 4.71 - 4.74 |
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Tue, 07 Oct 2025
Arbutus Biopharma Showcases Data at Liver Meeting 2025 - TipRanks
Tue, 07 Oct 2025
Arbutus Biopharma (ABUS) Showcases Promising Liver Disease Resea - GuruFocus
Mon, 15 Sep 2025
Arbutus: IP Drama With High Stakes (NASDAQ:ABUS) - Seeking Alpha
Mon, 01 Sep 2025
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? - sharewise.com
Mon, 01 Sep 2025
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Wed, 06 Aug 2025
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 192 (M) |
| Shares Float | 126 (M) |
| Held by Insiders | 21.8 (%) |
| Held by Institutions | 62.5 (%) |
| Shares Short | 9,860 (K) |
| Shares Short P.Month | 11,160 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.43 |
| Profit Margin | 0 % |
| Operating Margin | 17.8 % |
| Return on Assets (ttm) | -21.1 % |
| Return on Equity (ttm) | -52.9 % |
| Qtrly Rev. Growth | 522.2 % |
| Gross Profit (p.s.) | -0.2 |
| Sales Per Share | 0.08 |
| EBITDA (p.s.) | -0.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -60 (M) |
| Levered Free Cash Flow | -35 (M) |
| PE Ratio | -16.25 |
| PEG Ratio | 0 |
| Price to Book value | 10.95 |
| Price to Sales | 58.55 |
| Price to Cash Flow | -15.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|